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      The Michel addition of styrylisoxazoles with ethyl benzoyl acetate in presence of         p-
toluene sulfonic acid (PTSA) catalyst supported on KSF solid furnished the Michael adducts in 
excellent yields in short time. The Michael adducts underwent reductive cyclization on treatment 
with SnCl2- MeOH to afford isoxazolo [4,5-b] azepines in high yields. 
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Introduction 
        Heterocycles are widely utilized in both pharmaceutical and agricultural fields
1
. 
Consequently, the development of methodologies useful for the assembly of molecules 
containing heterocyclic templates continues to attract the attention of both the academic and 
industrial communities. Among the heterocycles, the isoxazole unit constitutes an easily 
accessible nucleus that is present in a number of natural and pharmacological compounds
2
. 
Azepine derivatives have been found to be associated with diverse pharmacological activities 






, vasopressin (AVP) 
antagonist activity
6
 and are employed as AMPA receptors
7
.     
    
        The Michael addition is one of the most efficient methods for effecting carbon-carbon bond 
formation
8
 and has wide synthetic applications
9
 and also useful in biosynthesis
10
. For Michael-
type reaction of 1,3-dicarbonyl compounds, several catalysts including chiral ones have been 
developed
11
. These reactions are usually carried out in a suitable solvent in presence of strong 
bases. When reaction is carried in the presence of strong bases, side reactions such as auto-
condensation, bis-additions, polymerizations, retrogressions and rearrangements are frequently 













 have been employed 
in the Michael addition. Yet, these procedures have one or more limitations with regard to the 
scope and generality of the reaction, use of the toxic and expensive materials, long reaction 
procedures and relatively low yield of the products. Thus, there is a need for new procedure that 
is convenient, reliable, easy to use and inexpensive. In view of this, we wish to disclose the use 
of PTSA catalyst (Lewis acid) supported on KSF to explore the Michael reactions very 
efficiently in excellent yields. As a sequel to our work on the synthesis of new fused heterocycles 
consisting of isoxazole as one of the moiety
16
, we herein, report the synthesis of new isoxazolo 
azepines via the Michael addition. 
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Results and Discussion 
 
       The Michael addition of 3-methyl-4-nitro-5-styrylisoxazoles
17
 1 with ethyl benzoyl acetate 2 
in presence of PTSA adsorbed on KSF were carried out in an oil bath at 120
o
C for 30 min. The 
reaction resulted in the formation of Michael adducts viz., ethyl-2-benzoyl-4-(3-methyl-4-nitro-
5-isoxazolyl)-3aryl butanoates 3 in 80-95% yields. The IR spectrum of 3 exhibited absorption 
bands due to carbonyl and ester functional groups at 1690 and 1725 cm
-1
. In the 
1
H NMR spectra 
of 3, three prominent signals as multiplites was observed around δ 3.6, 4.2 and 4.9 ppm for C4-
CH2, C3-H and C2-H protons respectively. The structure of 3 was further confirmed by recording 
its mass spectrum, which exhibited a molecular ion peak [ M+H ]
+
 at m/z 423.We have carried 
out PTSA catalyzed KSF solid supported synthesis of Michael adducts in an efficient manner 
and this report happens to be first of its kind to achieve the products without any undesired side 
products and the reaction is very efficient and completed in a short reaction time. This procedure 
offer significant improvement over the existing methods and invention of these products would 
thus help facile entry into a host of new Michael adducts of potentially high synthetic utility. 
 
 
     When the same reaction was carried out in refluxing triethyl amine or piperidine solvent 
according to reported procedure
18
, the product yield was approximately 50% and the reaction 
required nearly 2-4 h refluxing and the reaction resulted in by products
19
. In view of this, PTSA 
catalysed KSF solid supported Michael addition has greater advantage for reducing reaction time 
remarkably and the product yield is greatly enhanced and no side products are formed.  
 
     The Michael adducts 3 on heating with stannous chloride in methanol underwent reductive 
cyclization to afford ethyl-3-methyl-5-phenyl-7-aryl-7,8-dihydro-6H-azepino[2,3-d]isoxazole-6-
carboxylates 5 in high yields (75-88%). The Michael adducts are successfully converted to 
isoxazoloazepines 5 by reductive-cyclization process in a one-pot reaction (Scheme 1). The 
absence of a band at 1690 cm
-1
 in the IR spectra of these compounds 5 due to carbonyl 
absorption clearly indicates the reductive cyclization process. The  
1
H NMR spectra of 5 
displayed three multiplets around δ 3.60, 4.10 and 2.92 ppm due to C4-CH2, C6-H and C5-H 
protons respectively. The cycli-reduction was further ascertained by recording  mass spectrum of 
5a, which showed a molecular ion [ M+H ]
+
 peak at m/z 375. The structures of compounds 3 and 
5 have been elucidated by elemental analyses and spectral (IR, 
1
H NMR, Ms) data . 
 
      In conclusion, we have demonstrated a convenient and highly efficient protocol for the 
synthesis of isoxazoloazepines by conducting Michael reaction in presence of PTSA absorbed on 
KSF and the resulting Michael adducts are converted to isoxazoloazepines by reductive-
cyclization process in a one-pot reaction. This procedure offers significant improvement over the 
existing Michael reactions and all the reactions are clean, high yielding and the method is mild 
and tolerates several substituents on aromatic ring and devoid of forming any undesired side 
products. 
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                      3  &  5a,  Ar = C6H5                             3 &   5e, Ar =   4-CH3 C6H4 
                     3 &   5b, Ar =  4-ClC6H4                     3 &   5f, Ar =    2-ClC6H4 
                                3 &   5c, Ar =  4-CH3OC6H4                  3 &  5g, Ar =    2-HOC6H4 
                         3 &   5d, Ar =  4-HOC6H4                    3 &  5h, Ar =    3-ClC6H4 
 
     
 
                                                  Scheme I 
 
Experimental Section 
    Melting points are determined on a Cintex melting point apparatus and are uncorrected. The 
purity of the compounds was checked by TLC. IR spectra was recorded in KBr on Perkin Elmer 
spectrum BX series FT-IR spectrometer, 
1
H NMR spectra on a Varian Gemini 300 MHz 
spectrometer using tetramethyl silane as internal standard and mass spectra on a Jeol JMC-300 
spectrometer. The silica gel (0.040 x 0.063 mm) used  
for column chromatography was purchased from Merck. C, H and N analyses were carried out 





Preparation of  ethyl-2-benzoyl-4-(3-methyl-4-nitro-5-isoxazolyl)-3-aryl butanoates 3 
 
A mixture of 3-methyl-4-nitro-5-styrylisoxazole 1 (0.01 mol), ethyl benzoyl acetate 2 
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fuse for 30 min. to 1 h at 120
0
C in an oil bath. After completion of the reaction (monitored by 
TLC), it was allowed to cool. The solid mass was then taken in a column with a short plug of 
silica gel and eluted with ethylacetate and pet. ether (2:8). Evaporation of solvent furnished 
Michael adducts. 
 




HNMR (300 MHz, 
CDCl3) : δ 1.2 (t, 3H, CO2CH2CH3), 2.4 (s, 3H, isoxazole-CH3), 3.6-3.9 (m, 2H, C4-CH2), 4.1-4.3 





Compound 3b : IR (KBr): 
 




H NMR (300 MHz, 
CDCl3): δ 1.2 (t, 3H, CO2CH2CH3), 2.3 (s, 3H, isoxazole-CH3), 3.6-3.9(m, 2H, C4-CH2), 4.2-4.3 





Compound 3c: IR (KBr): 
 




H NMR (300 MHz, 
CDCl3): δ 1.2 (t, 3H, CO2CH2CH3), 2.3 (s, 3H, isoxazole-CH3), 3.5-3.8(m, 2H, C4-CH2), 3.9 (s, 
3H, OCH3), 4.2-4.4 (m, 2H, CO2CH2CH3 & 1H, C3-H), 4.9 (d, 1H, C2-H), 6.90-8.11 (m, 9H, Ar-




Compound 3d: IR (KBr): 
 




H NMR (300 MHz, 
CDCl3): δ 1.2 (t, 3H, CO2CH2CH3), 2.4 (s, 3H, isoxazole-CH3), 3.6-3.9(m, 2H, C4-CH2), 4.2-4.5 
(m, 2H, CO2CH2CH3 & 1H, C3-H), 4.8 (d, 1H, C2-H), 7.0-7.9 (m, 9H, Ar-H), 9.5     ( bs, 1H, 
OH, D2O exchangeable ). MS (EI)  : m/z  439 [M+H]
+
.  
 Compound 3e: IR (KBr): 
 




H NMR (300 MHz, 
CDCl3): δ 1.2 (t, 3H, CO2CH2CH3), 2.4 (s, 3H, isoxazole-CH3), 2.5 ( s, 3H, Ar- CH3 ),3.4-3.7(m, 
2H, C4-CH2), 4.2-4.5 (m, 2H, CO2CH2CH3 & 1H, C3-H), 4.7 (d, 1H, C2-H), 6.9-7.5  (m, 9H, Ar-




Compound 3f: IR (KBr): 
 




H NMR (300 MHz, 
CDCl3): δ 1.2 (t, 3H, CO2CH2CH3), 2.4 (s, 3H, isoxazole-CH3) 3.6-3.9 (m, 2H, C4-CH2), 4.1-4.4 





Compound 3g: IR (KBr): 
 




H NMR (300 MHz, 
CDCl3): δ 1.2 (t, 3H, CO2CH2CH3), 2.4 (s, 3H, isoxazole-CH3), 3.5-3.8 (m, 2H, C4-CH2), 4.0-4.4 
(m, 2H, CO2CH2CH3 & 1H, C3-H), 4.7 (d, 1H, C2-H), 6.8-7.3 (m, 9H, Ar-H), 9.8     ( bs, 1H, 




Compound 3h: IR (KBr): 
 




H NMR (300 MHz, 
CDCl3): δ 1.2 (t, 3H, CO2CH2CH3), 2.4 (s, 3H, isoxazole-CH3) 3.4-3.8 (m, 2H, C4-CH2), 4.1-4.3 
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Preparation of ethyl-3-methyl-5-pheny-7-aryl-7,8-dihydro-6H-azepino[2,3- d] isoxazole-6 
carboxylates  5 
 
         The Michael adduct 3a (0.01mol) and SnCl2.2H2O (0.05 mol) were dissolved in methanol 
(20 mL) and refluxed for 2-3 hr. After completion of the reaction (monitored by TLC), solvent 
was removed in vacuum. The solid mass was decomposed with cold water and the reaction 
solution was carefully adjusted to pH 8 with 10% NaHCO3 solution and then extracted with 
ethylacetate (2 x 20 mL). The combined organic layers were dried over Na2SO4 and evaporated 
under vacuum and purified by column chromatography. Elution with MeOH and pet. ether in 1:9 
ratio afforded isoxazolo azepines. 
 




H  NMR (300 MHz, CDCl3 δ 
ppm): 1.2 (t, 3H, CO2CH2CH3), 2.3 (s, 3H, isoxazole-CH3), 3.5-3.8(m, 2H, C8-H),4.1-4.3 (m, 





     Compound 5b: IR (KBr): 1610 ( C≡N ),1730 ( CO2Et )  cm
-1
  ; 
1
H NMR (300 MHz, CDCl3): 
δ 1.2 (t, 3H, CO2CH2CH3), 2.3 (s, 3H, isoxazole-CH3), 3.6- 3.9(m,2H, C8-H),  4.1-4.4 (m, 2H, 








H NMR (300 MHz, CDCl3 ): 
δ 1.2 (t, 3H, CO2CH2CH3), 2.3 (s, 3H,isoxazole-CH3), 3.5-3.8 (m, 2H, C8-H), 3.9(s, 3H, OCH3), 









H NMR (300 MHz, CDCl3 ): δ 
1.2 (t, 3H, CO2CH2CH3), 2.4 (s, 3H,isoxazole-CH3), 3.4-38 (m, 2H, C8-H), 4.2-4.4 (m, 2H, 
CO2CH2CH3 & 1H, C7-H), 4.7 (d,1H, C6-H), 6.8-8.0 (m, 9H, Ar-H), 10.0 ( bs, 1H, OH, D2O 








H NMR (300 MHz, CDCl3 ): δ 
1.2 (t, 3H, CO2CH2CH3), 2.3 (s, 3H,isoxazole-CH3), 2.5 ( s, 3H, Ar-CH3 ), 3.5-3.8 (m, 2H, C8-
H), 4.2-4.4 (m, 2H, CO2CH2CH3 & 1H, C7-H), 4.8 (d,1H, C6-H), 6.9-8.0 (m, 9H, Ar-H). MS(EI) 
: m/z 389 [M+H]
+
. 
    




H NMR (300 MHz, CDCl3 ): δ 
1.2 (t, 3H, CO2CH2CH3), 2.4 (s, 3H,isoxazole-CH3), 3.5-3.8 (m, 2H, C8-H), 4.1-4.4 (m, 2H, 








H NMR (300 MHz, CDCl3 ): δ 
1.2 (t, 3H, CO2CH2CH3), 2.3 (s, 3H,isoxazole-CH3), 3.4-3.7 (m, 2H, C8-H), 4.3-4.5 (m, 2H, 
CO2CH2CH3 & 1H, C7-H), 4.7 (d,1H, C6-H), 6.8-7.9 (m, 9H, Ar-H), 9.8 ( bs, 1H, OH, D2O 
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H NMR (300 MHz, CDCl3 ): 
δ 1.2 (t, 3H, CO2CH2CH3), 2.3 (s, 3H,isoxazole-CH3), 3.5-3.7 (m, 2H, C8-H), 4.0-4.4 (m, 2H, 
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Table – I  Characterization data of ethyl-2-benzoyl-4-(3-methyl-4-nitro-5-styryl)-3-phenyl 
butanoates  3a-h 








Mol.Formula Found (%) (Calcd) 
     C H N 

















  6.19) 
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Table – II Characterization data of ethyl-3-methyl-5-pheny-7-aryl-7,8-dihydro-6H-azepino[2,3- 
d] isoxazole-6 carboxylates  5a-h 
 








Mol.Formula Found (%) (Calcd) 
     C H N 

















  6.93) 
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